Evaluation of Immune Response Against the Strain of Neisseria Meningitidis B: 14, P1-7, 16 Patients Vaccinated With MenBVac® (Extension MenbVac)

Phase 3CompletedNCT01565577

University Hospital, Rouen117 enrolled

Overview

This study aims to estimate the vaccinal immunity four years after four doses of MenbVac in children aged 4-8 years.

Study Type

INTERVENTIONAL

Allocation

Purpose

HEALTH_SERVICES_RESEARCH

Masking

NONE

Enrollment

117

Conditions

Vaccination With MenbVac

Interventions

MenbVacBIOLOGICAL

Blood test

Eligibility

Sex: ALLMin age: 7 YearsMax age: 12 YearsHealthy volunteers:

Medical Language ↔ Plain English

Inclusion Criteria: * children born between 01/01/2000 and 06/23/2005, living in Dieppe-Est, Dieppe-Ouest and Offranville, vaccinated with four doses of MenBVac in the first MenbVac clinical trial study, * parental authority(ies)assent. Exclusion Criteria: * no parental authority(ies)assent, * no parental authority(ies)assent, * no blood sample during the third vaccination, * impossibility of third vaccination.

Locations (1)

UH-rouen

Rouen, Seine Maritime, France

Outcomes

Primary Outcomes

vaccine Immunity

assessment of vaccine Immunity with measure of percentage of children with an hSBA title \>= 4 four years after four doses of MenbVac

Time frame: two and a half years after the fouth vaccination

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.